Results from two Canadian studies confirm sustained viral response rates seen in hepatitis C patients treated with PEGETRON(R) Nov 2, 2009
" These results reinforce the notion that outcomes achieved with PEGETRON across a large number of clinical trials are consistent and could be generalized to real-life clinical practice.(3) The Future of Hepatitis C Therapy In addition to the POWeR and REDIPEN studies, clinical trial data for Schering-Plough's investigational HCV protease inhibitors boceprevir and narlaprevir (SCH 900518) were presented at AASLD. Researchers analyzed data from the Phase II HCV SPRINT-1 study to determine SVR... (Canada Newswire)
Extending treatment after liver transplant may benefit patients with hepatitis C recurrence Nov 1, 2009
"We found that patients who achieved a sustained virological response were more likely to have had extended treatment," says Kimberly Brown, M.D., Division head of Gastroenterology at Henry Ford Hospital and senior author of the study ... Of the study patients with hepatitis C, 66 were eligible for treatment, and 22 achieved sustained virological response ... After week 24 of treatment, 35 percent of patients who achieved a sustained virologic response became virus negative. (EurekAlert!)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Hepatitis C Oct 29, 2009
6 issue)1 report a similar rate of sustained virologic response among patients who received low-dose peginterferon alfa-2b plus ribavirin and patients who received other regimens. Although the groups of patients who received ribavirin plus either peginterferon alfa-2a or standard-dose peginterferon alfa-2b had a more favorable decrease in on-treatment viral loads than the group that received low-dose peginterferon alfa-2b plus ribavirin, the higher relapse rates among the former groups... (New England Journal of Medicine)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection Aug 6, 2009
We compared the rate of sustained virologic response and the safety and adverse-event profiles between the peginterferon alfa-2b regimens and between the standard-dose peginterferon alfa-2b regimen and the peginterferon alfa-2a regimen. Results Among 3070 patients, rates of sustained virologic response were similar among the regimens: 39 ... Among the patients with undetectable HCV RNA levels at treatment weeks 4 and 12, a sustained virologic response was achieved in 86. (New England Journal of Medicine)
Botswana: Mother-to-Child HIV Transmission Lowest in Africa - Study Jul 30, 2009
This was revealed by Dr Roger Shapiro of the Botswana-Havard AIDS Institute when releasing the findings of a random trial comparing HAART regimens for virologic efficacy and the prevention of mother-to-child HIV transmission among breastfeeding mothers in Botswana at Boipuso Hall in Gaborone last Friday. The Mmabana Study, as the programme is called, also revealed that Maternal Highly Active Antiretroviral Therapy (HAART) from early in the third trimester of pregnancy through six months of... (allAfrica.com)
Telaprevir for Chronic HCV Infection Jul 30, 2009
Combined data from all telaprevir regimens in both trials show a significant difference in sustained virologic response between patients completing and those discontinuing treatment (78% and 25%, respectively; P<0. 001). (New England Journal of Medicine)
At least 1 million H1N1 flu cases in US Jun 27, 2009
" onclick="Next();" src="/images/butt_next (Channelnewsasia.com)
New Treatment Option For Patients With Chronic Hepatitis C Jun 2, 2009
6 percent, was observed in noncirrhotic patients who had a partial virologic response with a greater than 2-log10 decline in HCV RNA during their previous course of peg-IFN treatment, the authors report ... The greatest SVR rate during retreatment in the present study was observed in F0-F3 patients who had a partial virologic response during their prior course of treatment. (Science Daily)
Boceprevir eliminated Hep C virus in unprecedented number of patients May 26, 2009
Patients that received a 48-week boceprevir regimen achieved a 75 per cent SVR rate, twice the efficacy rate provided by current standard therapies KIRKLAND, QC, May 26 /CNW/ - Schering-Plough Canada announced today that final results of the HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1) study showed boceprevir - its investigational oral hepatitis C protease inhibitor - in combination with PEGETRON(R) (peginterferon alfa-2b and ribavirin), significantly increased sustained virologic... (Canada Newswire)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Infection Apr 30, 2009
The primary outcome was a sustained virologic response (an undetectable HCV RNA level 24 weeks after the end of therapy). Results The rate of sustained virologic response was 41% (31 of 75 patients) in the PR48 group, as compared with 61% (48 of 79 patients) in the T12PR24 group (P=0 ... Conclusions Treatment with a telaprevir-based regimen significantly improved sustained virologic response rates in patients with genotype 1 HCV, albeit with higher rates of discontinuation because of adverse... (New England Journal of Medicine)
Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 Apr 15, 2009
In addition, the research provides profiles of 10 publicly traded U.S. laboratory and pathology companies: Bio-Reference Laboratories, Enzo Biochem, Genzyme Genetics, Laboratory Corporation of America, Medtox Scientific, Myriad Genetics, Psychemedics Corporation, Quest Diagnostics, Monogram Biosciences (Formerly ViroLogic, Inc.) and NeoGenomics. Each profile subsumes critical contact info (address, telephone, email, fax, names of leading employees (e. (PR Newswire)
Education Slowing AIDS In Sub-Saharan Africa Mar 29, 2009
14, 2008) HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking. (Dec. (Science Daily)
Prolonged Therapy for Hepatitis C with Low-Dose Peginterferon Mar 12, 2009
Although antiviral therapy for hepatitis C improves surrogate outcomes (alanine aminotransferase levels, histologic changes, and sustained virologic responses), these surrogates have never been validated. 2 In the HALT-C trial, maintenance therapy with peginterferon therapy improved inflammatory markers (alanine aminotransferase levels and necroinflammatory histologic findings) and reduced viral titers (producing more sustained virologic responses) without affecting clinical outcomes. (New England Journal of Medicine)
